Surprising CPAP Findings Should Not Discourage Development – NEJM
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers should continue to develop continuous positive airway pressure technology to improve cardiovascular outcomes, despite a new trial showing that the procedure does not improve mortality in heart failure patients with central sleep apnea, according to an editorial in the Nov. 10 New England Journal of Medicine.
You may also be interested in...
Atrial Overdrive Pacing Could Benefit Some Sleep Apnea Sufferers – NEJM
Atrial overdrive pacing will continue to play only a small role in the treatment of sleep apnea, Daniel Gottlieb, MD, Boston University predicts in a New England Journal of Medicine editorial
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.